|
CP110 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.63424829224823E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.6858736628933E-12 |
| Normal-vs-Stage2 |
5.58442181386454E-14 |
| Normal-vs-Stage3 |
1.62680979798324E-12 |
| Normal-vs-Stage4 |
1.11022302462516E-16 |
| Stage1-vs-Stage2 |
3.553200E-01 |
| Stage1-vs-Stage3 |
1.193010E-01 |
| Stage1-vs-Stage4 |
7.720100E-03 |
| Stage2-vs-Stage3 |
8.203000E-01 |
| Stage2-vs-Stage4 |
2.419800E-01 |
| Stage3-vs-Stage4 |
2.821000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63624669369256E-12 |
| Normal-vs-AfricanAmerican |
1.73809966419469E-10 |
| Normal-vs-Asian |
3.18778337060621E-12 |
| Caucasian-vs-AfricanAmerican |
9.559800E-01 |
| Caucasian-vs-Asian |
5.505600E-01 |
| AfricanAmerican-vs-Asian |
7.175800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62525548574877E-12 |
| Normal-vs-Female |
1.64612767861172E-12 |
| Male-vs-Female |
7.698300E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.99440505513849E-14 |
| Normal-vs-Age(41-60Yrs) |
1.14352971536391E-14 |
| Normal-vs-Age(61-80Yrs) |
5.55111512312578E-16 |
| Normal-vs-Age(81-100Yrs) |
2.48210000000082E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.469000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.647900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.587200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.036600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.667800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.662800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.572320E-04 |
| Classical-VS-Follicular |
5.981800E-02 |
| Classical-VS-Other |
4.624600E-01 |
| Classical-VS-Normal |
8.85180817533637E-13 |
| Tall-VS-Follicular |
8.391700E-02 |
| Tall-VS-Other |
2.851200E-01 |
| Tall-VS-Normal |
3.33066907387547E-16 |
| Follicular-VS-Other |
9.938400E-01 |
| Follicular-VS-Normal |
1.65500946280872E-12 |
| Other-VS-Normal |
2.438200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.55111512312578E-15 |
| Normal-vs-N1 |
1.63158375698913E-12 |
| N0-vs-N1 |
5.617000E-01 |
|
|
